ZYBERNO
Stock Report
Updated Jun 7, 2026

CYPHERPUNK TECHNOLOGIES INC. (LPTX)

Healthcare • NASDAQ

$0.58

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
CYPHERPUNK TECHNOLOGIES INC. (LPTX) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-92.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-28.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CYPHERPUNK TECHNOLOGIES INC. (LPTX) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.58
Market Cap:$97.50M

Valuation Multiples (2)

P/B Ratio:1.16x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$90.89M
B. Profitability Assessment

Return Metrics (5)

ROA:-80.7%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$3.45
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-36.0%
Latest Earnings Filed:2026-05-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:27.28x
Quick Ratio:27.28x
Cash Ratio:2.23x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1,642.68x
Times Interest Earned:-1,642.68

Capital Structure (4)

Working Capital:78,919,000.00
Cash And Cash Equivalents:6,689,000.00
Long Term Debt:$38.00K
Net Debt:-$6.61M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$29.97M

Bottom Line Performance (3)

-$56.91M
Income Before Tax:-$113.67M
Ebitda Ttm:-29,967,000.00

Operating Expenses (5)

Operating Expenses:29,967,000.00
R And D Expense:12,920,000.00
Sga Expense:12,520,000.00
Income Tax Expense:-$5.12M
Interest Expense:25,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$87.38M
Current Assets:$81.92M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,003,000.00
Current Liabilities:3,003,000.00
Long Term Debt:$38.00K
Short Term Debt:$38.00K

Equity & Capital (3)

Equity:$84.38M
Retained Earnings:-$539.72M
Common Stock:490,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,966,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,131,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$32.85M$0.00

Investment Activities (1)

Investing Cash Flow:-$9.00M

Financing Activities (3)

Financing Cash Flow:$5.08M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.02
-$0.02
Earnings Per Share Ttm:-$0.34

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.26

Book Value & Capital (2)

Book Value Per Share:$0.50
Cash Per Share:0.04

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-28.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:LPTX
Company Name:CYPHERPUNK TECHNOLOGIES INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:168.10M
Shares Outstanding Basic:168.10M
Shares Outstanding Diluted:168.10M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-07 11:44:43 UTC
Data Timestamp:2026-06-07T11:44:43.597555
Scroll to Top